Gaucher disease: in vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypes

Am J Med Genet A. 2003 Jan 1;116A(1):52-6. doi: 10.1002/ajmg.a.10029.

Abstract

Gaucher disease, a common lysosomal storage disorder, is associated with mutations at the acid beta-glucosidase (GCase) locus. Two affected individuals are described to share a common mutant allele, but manifest different clinical categorical phenotypes. A 57-year-old female, with Gaucher disease type 1 and Cherokee ancestry, was homozygous for a rare mutant allele encoding Lys79Asn (K79N). A 2-year-old Caucasian male, with Gaucher disease type 3 and Cherokee ancestry, was a heteroallelic homozygote for this same allele (K79N) and a novel complex mutation (null allele). The shared alleles were identical as determined by complete gene sequencing, suggesting a founder effect. The discrepant phenotypes (types 1 and 3) in these two patients provide support for a threshold of residual activity necessary to "protect" the central nervous system (CNS) from the pathogenic effects of Gaucher disease, indicating an allele dose-effect. Designation of genotype associations with specific phenotypes must be assessed with this perspective.

Publication types

  • Case Reports

MeSH terms

  • Alleles
  • Child, Preschool
  • DNA / chemistry
  • DNA / genetics
  • DNA Mutational Analysis
  • Female
  • Gaucher Disease / enzymology
  • Gaucher Disease / genetics*
  • Gaucher Disease / pathology
  • Glucosylceramidase / deficiency
  • Glucosylceramidase / genetics*
  • Haplotypes
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Mutation, Missense
  • Phenotype

Substances

  • DNA
  • Glucosylceramidase